Thursday, 24 January 2019

Uptick Newswire Hosts BioLargo, Inc.’s CEO to Discuss the Company’s Outlook for 2019 and Share its 2018 Milestones



PHOENIX, Jan. 24, 2019 (GLOBE NEWSWIRE) — Uptick Newswire Stock Day Podcast welcomed BioLargo, Inc. (OTCQB:BLGO) (“The Company”), a developer of sustainable science and technologies and a full-service environmental engineering company. Dennis Calvert, the President and CEO of BioLargo, Inc., talked with Stock Day’s Everett Jolly.
Jolly began the interview by inquiring about the Company’s milestones for 2018. Calvert explained that the Company’s product, Odor-No-More, broke over $1 million in revenue, and that they also signed one of the leading companies in the waste handling industry. Between revenue and grants, the Company generated nearly $2 million for 2018.
Calvert also shared that $1 million was raised in working capital for their recently acquired stem cell therapy technology SkinDiscTM, which as a direct investment doesn’t require subsidy by the corporate office. Another milestone included the Company’s engineering group, which experienced instrumental growth during the 4th quarter of 2018.
Calvert also explained the company’s expectations for 2019, “In a blink, we could go to $300,000 per month or more in revenue.” Calvert explained that the Company is positioned well to achieve this and simply needs to keep growing steadily. He also shared that their current products have grown to a point where they are ready for partners, such as distributors or acquisitions. “We’re shifting away from let’s do it ourselves,” said Calvert.
Calvert then explained how the Company will maintain its cash flow. “We made a major shift at the end of the year. We made some cutbacks in the R&D budget and staff and redirected it into a decidedly commercial track to reduce our burn rate and focus on getting through these pilots that are sponsored with grants,” said Calvert.
To close the interview Jolly asked Calvert why investors should take a look at BioLargo Inc. for 2019. Calvert stated, “We’ve got revolutionary technology that is destined to rise to the top.” He shared that the Company has demonstrated its commercial viability and has the potential to experience rapid growth. Looking forward, Calvert expressed his excitement for what lays ahead, and further shared that the key is to properly capitalize and get the infrastructure in place.
Investors Hangout is a proud sponsor of “Stock Day,” and Uptick Newswire encourages listeners to visit the company’s message board at https://investorshangout.com/
About BioLargo, Inc.
BioLargo, Inc. is an innovative technology developer and environmental engineering company driven by a mission to “make life better” by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air, and advanced wound care. We develop and commercialize disruptive technologies by providing the capital, support, and expertise to expedite them from “cradle” to “maturity” (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System “AOS”, a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. Our subsidiary Clyra Medical (www.clyramedical.com) features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.
Contact Information Dennis Calvert President and CEO BioLargo, Inc. 949-643-9540 x2
Safe Harbor Act
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.
About Uptick Newswire and the “Stock Day” Podcast
Founded in 2013, Uptick Newswire is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Uptick provides companies with customized solutions to their news distribution in both national and international media outlets. Uptick is the sole producer of its “Stock Day” Podcast, which is the number one radio show of its kind in America. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire, which recently launched its Video Interview Studio located in Phoenix, Arizona.

Wednesday, 23 January 2019

Letter to Stockholders: BioLargo Breaks New Revenue Records in 2018 and Forecasts Positive Cash Flow in 2019


Dear Stockholder,

I write to provide an update on the significant progress and improvements our business units made in 2018 and to share some insight into our plans to achieve significant growth and positive cashflow going forward in 2019.

While we’ve had to overcome many challenges in 2018, it was also a turning point for our company. We substantially increased our revenues, pulled in more cash from grants, tightened our R&D belts, and secured direct investment of $1 million into Clyra as we acquired a stem cell therapy technology. Last but certainly not least, we also advanced the position of our most important asset – our patented technology – to a state where we expect it will soon bear the fruits of our significant investments of time, money and labor.

Our mission is now to capitalize on the significant opportunities we have created.

Looking back at 2018

Notable milestones:
  • Our odor division Odor-No-More, Inc. topped $1.1 million in revenue. It recently signed agreements with the leading company in the waste handling industry for our patented industrial odor eliminator CupriDyne Clean®. It has also been featured by the waste water treatment industry as a ‘best practices’ and continues to find new markets anxious for a solution like ours.  ONM also launched a full-service design, build, installation, and maintenance team for the odor market. All these achievements combine to set us up to hit a growth rate of two to three times or more for the odor and VOC control business in 2019, assuming basic working capital is in place.
  • AOS water treatment technology has entered into its first pre-commercial pilots to prove its operational and capital costs (OPEX/CAPEX) and to pave the way for commercial trials and market entry. The importance of this step in its development cannot be overstated – it is the cornerstone for the commercialization of the AOS for water treatment.
  • Our Canadian research team achieved technical milestones in AOS development, secured funding for pre-commercial pilots, developed a new a “spiral” AOS reactor, reported results of third-party study that showed the AOS can treat and reduce the toxicity ofmicropollutants associated with municipal wastewater, and was awarded its 66th grant.
  • Total cash from all revenues and grant support (to us and to third parties supporting our research projects) in 2018 was almost $2M. We expect these numbers will increase dramatically in 2019, primarily as a result of rising revenues in our odor and engineering business units.
  • Clyra has multiple product designs and continues to progress through the FDA 510(k) review process on its first (which we remain confident about).
  • We acquired a revolutionary stem cell therapy technology and raised $1M in direct investments into the Clyra subsidiary.
  • Engineering subsidiary BLEST completed its first year in business trending toward profitability, and its third-party service billings even exceeded expenses during Q4 2018.

Overcoming Hurdles

Our journey to success requires us to overcome barriers to entry, capital constraints and events beyond our control.  You don’t have to look far to see the impact of a government shut-down, regulatory hurdles that cost time and money, and extreme volatility in the global capital markets.  We have continued to remain steadfast in the face of these hurdles.

Our response is straight forward:
  • We have focused on serving our clients, growing revenue, and adding strategic services to lock in a leadership role in the odor and VOC control market;
  • We have refocused our efforts in Canada towards our pre-commercial pilot opportunities at a poultry processing plant, micro-brewery, and storm wastewater treatment plant, reducing our R&D budget and staff at the end of 2018 (and thus our operating costs);
  • We have created and are executing on a specific plan to complete requests made by the FDA to complete Clyra’s 510(k) application in review;
  • Our senior management continued to demonstrate confidence in our future by foregoing substantial cash compensation and instead accepting restricted (locked up) shares of common stock (still no stock sales from management since inception) to preserve capital; and
  • We continue the ongoing search for longer-term investment capital to support our vision of tremendous growth, positive cash flow and high impact.

Looking forward to 2019

We believe that with proper capital resources we can grow top line revenues and achieve a cash flow positive status in 2019.  We are definitely heading in the right direction – increasing revenues from our business units have reduced demands on capital support from the corporate office. Our goals for the coming year are:
  • Increase odor product sales to generate positive cash flow and cover all base operations. We forecast that sales in the $350k - $450k range per month could generate sufficient cash flow to support Odor-No-More, the base operations of the corporate office, and the current low level of capital support for R&D to complete the current pilot work planned for our water business unit;
  • Secure distribution partners for our odor products in the wastewater treatment segment;
  • Achieve approval of our FDA 510(k) application, secure more direct investment into Clyra, and launch the product. Clyra has been funded by direct investment into the subsidiary from outside investors and this is expected to continue going forward;
  • Complete pre-commercial pilots for the AOS, paving the way for commercial pilots, manufacturing, and market entry;
  • Secure direct investment into BioLargo Water;
  • Complete uplist to Nasdaq or equivalent national market; and
  • Pay off all debt.

Closing

There is no substitute for innovation.  Original revolutionary ideas will always rise to the top.’
Sir Richard Branson

A few days ago, one of our first investors said to me, “remember to remind everyone about the revolutionary nature of your technologies”. The investor was right: BioLargo epitomizes the principles of innovation as we have created, proven, and are now commercializing three high-impact sustainable platform technologies covered by 18 patents, 5 patents pending, 66 research/government grants, and countless scientific studies. Our history is marked by significant investment in R&D (more than $6M since 2007) to build out our robust intellectual property portfolio. While certainly there have been hurdles and there are hurdles yet to come, those investments in R&D have yielded incredibly important technology assets with the potential to create tremendous value for our company, our investors, and the world.

The task ahead of us now is to leverage these technology assets by properly capitalizing and monetizing them through commercialization, licensing or sale. That’s exactly what we plan to do in 2019. We hope you will be with us as we rise to the top!

Sincerely,

Dennis P. Calvert
President & CEO
BioLargo, Inc.

Wednesday, 26 December 2018

BioLargo President and CEO Dennis Calvert's Video Interview with SNNLive at LD Micro Main Event XI

BioLargo President and CEO Dennis Calvert recently presented at the LD Micro Main Event XI in Los Angeles on December 4th. At this investor conference Dennis sat down with SNNLive's Robert Kraft for a video interview about BioLargo's business and outlook for 2019.

Watch the whole video here:



BioLargo, Inc. (OTCQB: BLGO) is a technology developer and environmental engineering company driven by a mission to "make life better" by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air, and advanced wound care, according to the company’s website (see here: www.biolargo.com).
SNNLive caught up with Dennis Calvert, President & CEO of BioLargo, Inc. at the LD Micro "Main Event" 2018 in Bel Air, CA, and they discuss the following topics:
- Overview of BioLargo, Inc.
- Update since our last interview (click here)
- Industrial and VOC product
- What makes the company’s products unique in the marketplace
- Growth drivers going into 2019

For more information about BioLargo, Inc., please visit: www.biolargo.com

The interview may contain forward-looking statements about BioLargo, Inc. See BioLargo's periodic filings with the Securities and Exchange Commission for more complete information.

Wednesday, 19 December 2018

BioLargo Spotlight: OC Startups Now article Q&A - BioLargo’s Finances. Q&A with CEO Dennis Calvert…


OC Startups Now will periodically run Q&A’s with interesting entrepreneurs, investors and other key players in the OC startup/innovation ecosystem, in their own words.
This Q&A is with Dennis Calvert, CEO of BioLargo, a chemical company developing and marketing innovative products for a range of industries. Recent reports predicting the company’s demise have been exaggerated, Calvert said. It’s just business as usual for the 20-year-old company that is still in the startup stage.
The company’s core expertise is the unique chemistry of iodine, which it has leveraged to develop the following: an industrial odor control product (currently marketed as CupriDyne Clean); an irrigation solution for chronic wounds; and a wastewater treatment solution.
The goal is to build independent companies around each of these products, which can then be spun out, with BioLargo acting as the catalyst and development engine.
A recent financial report by Edison Investment Research shows that BioLargo is generating revenue, although it’s in the early early stages of commercialization. 
The company had revenue of $327,000 in Q2, a substantial increase year-on-year (compared to $100,000 in Q2 of 2017). The net loss for Q2 was $3.6 million, of which $1.7 million comprised non-cash payments associated with convertible notes. The majority of these notes have been recently converted (from $6.8 million at the end of 2017 to $2 million now) so this expense is expected to decrease this significantly.
OCSN: Talk about the conversion from debt to equity over the past decade.
Calvert: We’ve received about $23 million in investment over the past 10 years. We have about $1.2 million in near-term debt.
In the early years, we used debt financing to offer investors yield, but the underlying terms provided for mandatory conversion into equity.
The total investment has allowed us to take ideas and convert them to create four business units, three technical platforms, two commercial business units and two that are about to emerge from R&D.
OCSN: What are your four business units? And which are generating revenue now?
Calvert: Our first business unit is Odor No More. It developed CupriDyne Cleanan odor control agent marketed to the solid waste management and water treatment industries, with potential inroads into other industries, like composting and animal waste.
This unit is on the cusp of positive cash flow. It’s secured national purchasing agreements with four of the largest waste handling companies in the industry. It now includes engineering design, construction, service and maintenance so it’s a full-service provider.
Our second unit is engineeringIt’s just now reached the point ofsecuring contracts with outside customers, where revenue exceed expenses.
This unit was a new startup that was created by taking the innovation unit from one of the largest engineering companies in the industry, Chicago Bridge and Iron (CB&I). Earlier this year, CB&I merged into McDermott International
This unit has two goals: to supply internal services for BioLargo’s emerging tech and serve its own external clients to generate revenue.
The third business unit is Clyra Medical Technologies, a wound care startup that just announced a $1 million equity investment. (See related story here.)
BioLargo owns close to 50% of the equity. Cylra has received $3.5 million in equity investment to date.
The fourth unit deals, BioLargo Waterdeals with water purification. It’s a year away from commercialization. It’s in the midst of four pre-commercial pilots being sponsored by grants. It’s received 65 grants to date.
The water purification market is potentially a $750 billion market. We (recently) received independent validation on the ability of our tech to remove micropollutants.
OCSN: Are you still considering a reverse stock split with the goal of uplisting to NASDAQ? (In a special shareholder meeting in September, a reverse stock split was approved. It would take a raise of $5 million to meet this listing requirement.)
Calvert: In making the decision for a reverse stock split, the company needs equity investment, no question. We believe that a national exchange is really required and a company running on the OTC has become increasingly difficult to manage.
But, we also believe the national capital markets are under extreme pressure right now, so we are at the point of evaluating all of our capital resources that would allow us to achieve positive cash flow and consider the option of uplisting to a national exchange.
We’re evaluating our options on a daily basis.
OCSN: Anything else you’d like to add?
Calvert: We have 20 Ph.D.’s and engineers involved in our business. One of the challenges we have perpetually faced over our journey is the notion that our value propositions sometimes can appear too good to be true. Our response is they are in fact true.
What’s new is we’re now achieving a level of commercial validation and accumulation of third-party validations that reinforce our original claims. But that’s required significant time and investment to achieve critical mass to stand in front of the industry and have our tech be recognized as a disruptor.
I don’t mind criticism. We speak openly about the challenges we face as a disruptor for change.
When we went into waste handling industry, we positioned ourselves with truth, as the only product that actually works. That means the market had been trained that there was no product that actually worked. Everything was a band-aid, nothing was a fix. When we said we would solve it, the natural reaction is to say “We don’t believe you.”
The challenge is if you believe nothing works why would you do anything? In many of the things we’re doing, we’re presenting claims that in each case, it’s never been seen before. And therein lies the challenge.

BioLargo’s subsidiary Clyra Medical secures over $1 million in direct investments to finalize the acquisition of the breakthrough stem cell therapy technology SkinDisc



WESTMINSTER, Calif., December 19, 2018 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable science and technologies and a full-service environmental engineering company, announced today that its partially owned subsidiary Clyra Medical Technologies, Inc. has secured over $1 million in new capital via direct investment and finalized its acquisition of a breakthrough stem cell therapy technology called “SkinDiscTM”. Developed by Scion Solutions, LLC, SkinDiscTM uses a homogenous cocktail to generate a cell-rich bio gel that supports the healing of chronic wounds. The product has been deployed clinically in over 250 patient cases with no adverse side effects, and successfully aided in the salvage of limbs that otherwise may have led to amputation and costly treatments.
In addition to the acquiring the SkinDiscTM product, Clyra has engaged Scion’s founders to support its commercial strategy, including Dr. Brock Liden, a renowned wound specialist and expert in diabetic limb salvage, and Spencer Brown, a medical device industry veteran with more than 35 years of experience working in medical sales, account management, and distribution in the medical device industry. In addition to Dr. Liden and Mr. Brown, Scion’s founders include Tanya Rhodes, former VP of Innovation at Smith & Nephew, and a current Clyra consultant. The details of the Scion transaction were previously reported in a Form 8-K filed with the Securities and Exchange Commission on October 2, 2018 (link here).
Dennis P. Calvert, CEO of BioLargo commented, “Our core technologies are the foundation upon which we are building a successful company, and this is just one example. By funding Clyra through direct investment, we have secured dedicated capital to complete its products’ journey to market while also creating value for BioLargo’s shareholders through ownership in Clyra and its ongoing licensing arrangement. In this same vein, we intend to pursue direct investment for our BioLargo Water subsidiary in 2019. These developments serve to enhance the fundamental value of BioLargo while also helping to conserve capital.”
Calvert continued, “The completion of the Scion transaction is important for many reasons. First, a fairness opinion report written by an independent evaluator suggested that there is good evidence, based on comparable company analysis, that the combined value of Clyra and Scion would be approximately $33 million following this transaction. Second, the two technical platforms - Clyra antimicrobial products and the SkinDiscTM - represent substantial product platforms upon which to build an internationally competitive wound care company. Finally, Scion’s founders have successfully launched multiple products into the medical industry and bring crucial expertise on positioning our products in those markets. Of course, we remind our shareholders that we cannot predict the timing of the approval of our current application before the FDA, but that we are highly encouraged with the continued interaction with the FDA staff and believe we are on the right track to be successful soon.”
Clyra Medical’s antimicrobial technology feature a broad-spectrum of antimicrobial efficacy with no known acquired resistance, sustained release, biofilm efficacy, and bioharmony for skin and tissue. While Clyra realizes the need and opportunity across many medical disciplines, the initial targeted commercial markets will be in the areas of general wound therapy, infection control for the orthopedic surgery, and dental. The Clyra technology presents the potential for multiple additional product designs.
About BioLargo, Inc.
BioLargo, Inc. is an innovative technology developer and environmental engineering company driven by a mission to "make life better" by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air, and advanced wound care. We develop and commercialize disruptive technologies by providing the capital, support, and expertise to expedite them from "cradle" to "maturity" (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. Our subsidiary Clyra Medical (www.clyramedical.com) features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

Contact Information
Dennis Calvert President and CEO BioLargo, Inc. 949-643-9540 x2
Safe Harbor Disclosure
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Friday, 14 December 2018

BioLargo Spotlight: Introducing the Spiral AOS

In our previous blog posts that detailed the science behind BioLargo Water’s Advanced Oxidation System (AOS), we explained that the AOS treats water by generating reactive iodine molecules at its electrodes. The iodine molecules generated inside the AOS decontaminate and disinfect water in two fundamental ways: 1) by the oxidation of proteins inside bacteria, viruses, or protozoa and 2) by altering the structure of chemical pollutants, often breaking them down entirely. Explaining the mechanism of how the AOS works, we showcased just how effective the AOS is at reducing electrical and consumable costs while treating water. In this blog, we will elaborate upon recent radical design changes BioLargo Water has made to the AOS as part of our effort to continuously improve our technology, and we will illuminate how and why these decisions will result in a more effective and economical product for end-users.

Historically, AOS devices have conformed to a “stacked” design where water passes alternatingly through positive and negative electrodes one-by-one in a linear flow (see Figure 2, left side). The stacked AOS design is useful for a whole host of industrial applications, and its low cost and low energy value proposition still hold true. However, recent developments in AOS research and engineering design have yielded a new model of the AOS that has certain advantages over the stacked model for certain end-uses. Through development of the AOS, BioLargo Water discovered that the interface between positive electrodes and the spacer material is the most integral aspect of the AOS, being the location where much of the reactive iodine molecules are generated. This finding allowed the company’s scientists to exploit the interface’s benefits. As a result, BioLargo Water scientists designed a “Spiral” AOS device, with one positive electrode and one negative electrode coiled around each another multiple times. In maximizing the contact between water contaminants and the interface’s active chemicals, this design makes the decontamination and disinfection process dramatically more successful and efficient (Insert: image of spiral configuration).

Fig 1: Diagram of water flow through Spiral AOS













This spiral design has numerous benefits for customers. Beyond the obvious advantages of higher performance and lower energy requirements on a pound-for-pound basis, the “Spiral” AOS also significantly reduces the physical footprint. By reducing the size (by volume) of the AOS to approximately 1/5 of the older “Stacked” prototype, BioLargo Water’s design changes have transformed the AOS water treatment device to make the product more scalable, economically valuable, and commercially viable. With reduced spatial dimensions, the “Spiral” AOS is the most practical and feasible water treatment option for factories and consumer businesses that are already tight on space. The importance of this factor is illustrated by trends in the UV water disinfection market, where UV devices have grown progressively smaller over the years, allowing installation in tight spaces without causing operational disruption. It is clear that both industrial and consumer end-users prefer smaller water treatment devices.

Fig 2: Size comparison of old vs. new AOS
































We are excited about the Spiral AOS because it expands the ability for this technology to scale up for different end-user applications. As always, work continues at BioLargo to improve the technology further, and we are working to refine the physical substrate materials inside the AOS to ensure its durability and maintenance needs are optimised for commercial settings. Once we have completed our ongoing process of attaining patents (which are already on-file), and complete our pre-commercial testing, the “Spiral” AOS will be ready for commercial trials and market launch. It is only a matter of time before this novel and revolutionary device makes a major impact in the water treatment industry. When it does, BioLargo predicts that this powerful, flexible, cost-efficient, compact water treatment product has the potential to provide affordable water and wastewater treatment to myriad end-user applications. The possibilities for the Spiral AOS are innumerable.

Thursday, 6 December 2018

BioLargo Spotlight: Odor-No-More® Participates in Isle Utilities’ US TAG Events

Last week, BioLargo participated in two events put on by Isle Utilities, Inc., a leading clean tech accelerator group that operates globally in the water, waste, and energy sectors. These events are part of Isle Utilities’ Technology Approval Group (TAG) program, an innovation forum where leading early-adopter end-users, including major municipalities and utility companies, are exposed to innovative technology providers. Only a handful of companies are invited to each event, having been selected through a vote by end-user members.

Isle Utilities consists of a team of scientists, engineers, and industry experts from around the world, and they operate their TAG program in Europe, the US, Australia, Singapore, Brazil, and South Africa. According to their website, Isle Utilities is “an independent technology and innovation consultancy that brings together technical and commercial specialists to facilitate relationships. [Their] team are highly skilled engineers and scientists with extensive and diverse consulting experience”. Their TAG program is well-respected for its ability to identify disruptive new technologies for the water and wastewater sector.

To learn more about the TAG program, watch Isle Utilities’ video:



Isle Utilities has a thorough vetting process to choose companies for utilities to vote on to participate in US TAG events, including a rigorous technical review. This ensures that participating municipalities and utilities are only exposed to the very best innovative technology developers and product suppliers. The fact that BioLargo was invited to participate in TAG events represents important industry recognition of its innovative product CupriDyne® Clean.

BioLargo participated in the San Antonio, TX and Dayton, OH, TAG US events, where decision-makers representing municipal water utilities learned about the company’s disruptive industrial odor and VOC control product, CupriDyne Clean.

Odor-No-More’s Vice President of Industrial Sales AJ Sexton V represented the company. He commented on the events, “The Isle Utilities TAG events were terrific. We presented to over 60 people from regional utilities between the two meetings and had the opportunity to have direct one-on-one discussions with representatives from numerous potential clients. We applaud Isle Utilities for organizing these great events.”

US TAG attendees. Odor-No-More's AJ Sexton is 7th from the left

widget